CatalystFDA/Bio

$GALT

- GALECTIN DE-RISKS BELAPECTIN PATH WITH FDA ALIGNMENT — SETS STAGE FOR PHASE 3 UPSIDE

GALT

$4.14

-0.24%

What changed

- GALECTIN DE-RISKS BELAPECTIN PATH WITH FDA ALIGNMENT — SETS STAGE FOR PHASE 3 UPSIDE

Why it matters

FDA alignment de-risks belapectin, setting stage for phase 3 upside.

Sources